Tactiva Therapeutics is developing a next-generation adoptive cell therapy (ACT) that uses a dual approach to taking a patient's own T-cells and reprogramming them to attack cancer cells. Having licensed its technology, DEACT (dual enhanced adoptive cell therapy), from the Center for Immunotherapy at Roswell Park Cancer Institute, Buffalo, NY, Tactiva plans to begin Phase I/II basket trials, by the end of 2017, in five tumor types using a combination of hematopoietic stem cell-derived CD4 T-cell receptors (TCRs) and mature CD8 TCRs.
Tactiva Plans Cancer Trials For Next-Generation Cell Therapy
Emerging company profile: founded in early 2016, Tactiva Therapeutics licensed its adoptive cell therapy technology from Roswell Park Cancer Institute. CEO Matthew E. Colpoys told Scrip about the company's plans to raise funds to push its immunotherapy into clinical trials in five tumor types.
More from Start-Ups & SMEs
More from Business
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.